Article Text

PDF

OC-066 The Cancer Research UK (Cruk) Funded ICGC Oesophageal Adenocarcinoma Project: MRC Research Centre and Cruk Cambridge Research Institute
  1. JMJ Weaver1,
  2. N Shannon2,
  3. C Ross-Innes1,
  4. A Lynch2,
  5. T Forshew2,
  6. M Barbera1,
  7. C-A Ong1,
  8. P Lao-Sirieix1,
  9. M Dunning1,
  10. L Smith1,
  11. M Smith2,
  12. B Carvalho2,
  13. M O’Donovan3,
  14. T Underwood4,
  15. M Murtaza2,
  16. A May5,
  17. N Grehan3,
  18. R Hardwick3,
  19. J Davies6,
  20. A Oloumi7,
  21. S Aparicio8,
  22. N Rosenfeld2,
  23. M Eldridge2,
  24. C Caldas2,
  25. P Edwards1,
  26. S Tavare2,
  27. R Fitzgerald1
  1. 1Hutchison-MRC
  2. 2Cambridge Research Institute
  3. 3Addenbrooke’s Hospital, Cambridge
  4. 4Cancer Sciences Division, Southampton, UK
  5. 5Fluidigm Corporation, San Francisco, United States
  6. 6Oxford ComLab, Oxford
  7. 7British Columbia Cancer Research Centre, Cambridge, UK
  8. 8British Columbia Cancer Research Centre, Toronto, Canada

Abstract

Introduction Esophageal adenocarcinoma (EAC) has one of the fastest rising incidences of any cancer in the western world. With a 5-year survival below 10% it is one of the most common causes of cancer death in US and UK. Currently little is understood about the genetic alterations that drive the development of OAC. Better understanding of these alterations may allow the development of novel therepeutic approaches

Methods We have performed whole genome sequencing on 22 cases. Targeted amplicon resequencing of 27 recurrently mutated genes was performed on a validation cohort of 100 further oesophageal adenocarcinomas.

Results In the discover set of 22 OACs we identified recurrent mutations (>3 tumours) in 31 genes including several implicated in tumorigenesis; TP53, CDKN2A, ARID1A. Strikingly in the validation cohort we observed that > 30% of EAC samples harbour mutation of one or both of the SWI/SNF complex members ARID1A and SMARCA4. In addition we identified highly recurrent mutations in several additional genes including TRIM58, SSTR4 and MYO18B.

Conclusion Whole genome sequencing provides an unbiased screen of mutational architecture of OAC. This has allowed the identification of several recurrently mutated genes not previously implicated in this disease providing a unique insight to it’s pathogenesis

Disclosure of Interest None Declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.